Asphalion expands its presence with a new office in Pamplona

BHH member Asphalion, the Regulatory, Scientific, and Life Sciences Safety Consulting in the pharmaceutical industry, announces its expansion with this new office located in the MISO Centro space in the Pamplona Ensanche.

Asphalion offers a wide range of comprehensive services for drug development and regulatory affairs to pharmaceutical, biotechnology, and medical device companies. Their services span from the beginning of development, through registration, to product marketing and post-commercialization phases, as well as pharmacovigilance.

The Regulatory Consulting company began its activity in 2000 and has since continued to grow. "We are now more than 180 people, and our consultants have extensive experience in Sciences (Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine, and Veterinary Medicine, among others)," they add.

The consultants are experts in their field and are in direct contact with both national and international agencies for the development and implementation of new regulatory standards. "In addition to being leaders in Spain, we are also a reference in Europe and the United States, but we work for companies worldwide," they assure.

New headquarters in Pamplona after Barcelona, Madrid, Munich, and London

This strategic decision reflects the company's commitment to proximity to its clients and the strengthening of its presence in the national and international markets. The opening of the office in Pamplona adds to its already established headquarters in Barcelona, Madrid, Munich, and London and represents a significant milestone in Asphalion's growth, reinforcing its position as a leader in the field of regulatory, scientific, and safety consulting at a national level.

"At Asphalion, our core values revolve around a commitment to human talent and closeness to our clients. The opening of our office in Pamplona strengthens the development of Regulatory Talent and also helps us strengthen ties with our clients in the area. This step brings us even closer to our goal of providing solutions that facilitate the arrival of drugs that help improve our health to the market," explains Núria Romero, CEO of Asphalion.